Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Endoscopic ultrasound-guided gastro-enteric anastomosis: A systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Prevalence and diagnostic outcomes of children with duodenal lesions and negative celiac serology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Screen-detected gallstone disease and autoimmune diseases - A cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Influence of NAFLD and bariatric surgery on hepatic and adipose tissue mitochondrial biogenesis and respiration

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Letter: the clinical course of Crohn's disease-the Sicilian experience. Authors' reply

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Determination of hepatic clearance by derivations of the indocyanine green retention test in cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Praktisk anvendelse af thiopuriner hos patienter med kronisk inflammatoriske tarmsygdomme

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

BACKGROUND: The efficacy and safety of vedolizumab in bio-naïve patients with ulcerative colitis (UC) and Crohn's disease (CD) remain unknown.

AIMS: To perform a meta-analysis regarding vedolizumab as first line of biological therapy for UC or CD.

METHODS: A systematic review of Medline, EMBASE, and Cochrane databases per December 2020 was undertaken. Meta-analysis was conducted using random-effects models.

RESULTS: This systematic review identified 79 eligible studies with 4,520 and 3,494 bio-naïve patients with UC and CD, respectively, and 8,105 and 11,140 bio-exposed patients. Among bio-naïve patients with UC, a total of 40.0% (95%CI 27.0-54.0, I2=86%) and 63.9% (95%CI 47.0-79.2, I2=36%) achieved clinical remission at weeks 14 and 52, respectively. The corresponding rates in CD were 54.0% (95%CI 42.0-66.0, I2=23%), and 61.7% (95%CI 55.2-68.1, I2=0%). Bio-naïvety was associated with a higher probability of clinical remission at week 52 in UC (relative risk (RR)=1.32 (95%CI 1.14-1.53)), while this was only apparent until week 26 in CD (RR=1.60 (95%CI 1.30-1.95)). Finally, bio-naïve UC patients had a lower risk of serious adverse events (RR=0.29 (95%CI 0.09-0.95)).

CONCLUSION: Vedolizumab was found to have a favorable efficacy and safety profile in bio-naïve patients with UC and CD. The findings have implications in the management of IBD.

OriginalsprogEngelsk
Artikelnummer00856-2
TidsskriftDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Sider (fra-til)1-11
Antal sider11
ISSN1590-8658
DOI
StatusE-pub ahead of print - 10 dec. 2021

Bibliografisk note

Copyright © 2021. Published by Elsevier Ltd.

ID: 70539767